Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Amortizatization of Intangibles (2021 - 2026)

SAB Biotherapeutics filings provide 6 years of Amortizatization of Intangibles readings, the most recent being $22000.0 for Q1 2026.

  • On a quarterly basis, Amortizatization of Intangibles changed 0.0% to $22000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $100883.0, a 0.12% change, with the full-year FY2025 number at $100000.0, changed 0.0% from a year prior.
  • Amortizatization of Intangibles hit $22000.0 in Q1 2026 for SAB Biotherapeutics, down from $34883.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $41207.0 in Q1 2022 to a low of $2267.0 in Q4 2022.
  • Median Amortizatization of Intangibles over the past 5 years was $22000.0 (2023), compared with a mean of $24441.7.
  • Biggest five-year swings in Amortizatization of Intangibles: tumbled 94.5% in 2022 and later soared 866.48% in 2023.
  • SAB Biotherapeutics' Amortizatization of Intangibles stood at $2267.0 in 2022, then soared by 866.48% to $21910.0 in 2023, then surged by 59.74% to $35000.0 in 2024, then dropped by 0.33% to $34883.0 in 2025, then tumbled by 36.93% to $22000.0 in 2026.
  • The last three reported values for Amortizatization of Intangibles were $22000.0 (Q1 2026), $34883.0 (Q4 2025), and $22000.0 (Q3 2025) per Business Quant data.